Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1330Breast Neoplasms 686Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 436Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 364Lymphoma, Non-Hodgkin 355Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 266Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 252Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Carcinoma, Renal Cell 193Hodgkin Disease 192Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Burkitt Lymphoma 172Glioma 171

Interventions

Methadone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Completed × Breakthrough Pain × Clear all
NCT00125294 2017-09-25

Sublingual Methadone for the Management of Cancer Breakthrough Pain

AHS Cancer Control Alberta

Phase 1 Completed
10 enrolled

Cancer Pain, Neoplasms, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡